Literature DB >> 11792088

Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials.

A I Adler1.   

Abstract

Diabetes markedly increases the risk of coronary artery disease and death, but is underrecognised as a cardiovascular risk factor, despite the existence of effective treatments. Because patients with diabetes are at high risk for coronary disease, they have more to gain from prevention. There is evidence from clinical trials that select cardiovascular therapies may work better in diabetes, beyond their expected benefit, and may prevent diabetes itself.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11792088      PMCID: PMC4953875          DOI: 10.7861/clinmedicine.1-6-472

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  4 in total

Review 1.  Endoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseases.

Authors:  Mei-qing Liu; Zhe Chen; Lin-xi Chen
Journal:  Acta Pharmacol Sin       Date:  2016-02-01       Impact factor: 6.150

2.  Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors:  Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal:  Can J Cardiol       Date:  2006-09       Impact factor: 5.223

Review 3.  Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors:  Andrew J Krentz; Clifford J Bailey
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Can blood glucose value really be referred to as a metabolic parameter?

Authors:  Kornél Simon; István Wittmann
Journal:  Rev Endocr Metab Disord       Date:  2019-06       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.